Chinese Firm to Mass Produce Military Developed Vaccine
One Chinese firm is planning to mass produce a military developed vaccine against the Ebola virus as the epidemic had contributed to the deaths of more than 11,000 people in West Africa starting to fade. The firm, which is privately held by Tianjin CanSino Biotechnology Inc., is planning to invest around 2 billion yuan to create a facility in the northeastern city of Tianjin and begin to produce the vaccine.
The facility is set to be completed by 2018 although there is no date set yet on when the production of the vaccine will start. The vaccine has been developed by a team at the China’s Academy of Military Medical Sciences. China approved the experimental vaccine for clinical trials last year as the country move amongst the global leaders in the development of vaccine that is used to treat the disease. There are new cases of Ebola dwindled this year and earlier this month the three West African countries which the epidemic is rampant recorded its first week of no new cases since the outbreak in March of 2014.
There is already one successful Ebola Vaccine released and manufactured by Merck and NewLink Genetics that is already proven to be 100 percent effective in a clinical study in Guinea and earlier this month a U.S. firm Johnson & Johnson has started a clinical trial of a two shot Ebola vaccine in Sierra Leone.